Ticada Tablet 90mg (Ticagrelor)

Adult dose

Do not use this medicine concomitantly with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). ㆍAcute coronary syndrome: Administer an initial dose of 180mg, followed by 90mg twice daily. Treatment for 12 months is recommended unless discontinuation is clinically necessary. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. ㆍPatients with a history of myocardial infarction (occurring at least 1 year previously) who are at high risk of thrombotic cardiovascular events: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. - Patients who took this medicine 90mg or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with this medicine 60mg. - Treatment with this medicine may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuing a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). - The safety and efficacy of this medicine were evaluated at 3 years of follow-up. ㆍPatients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. - Refer to the corresponding dosage and administration for patients with acute coronary syndrome. - Data on the safety and efficacy of treatment with this medicine for more than 3 years are limited. ㆍPatients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180mg, followed by 90mg twice daily for 30 days. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended for patients with acute ischemic stroke or high-risk transient ischemic attack. Method of administration This medicine is administered orally and may be taken with or without food. ㆍFor patients who have difficulty swallowing the tablet, crush this medicine into a fine powder, disperse it in half a glass of water, and drink it immediately. Rinse the glass used with half a glass of water and drink the rinse. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the tube with water after administration. ㆍWhen switching from another antiplatelet agent to this medicine, start this medicine 24 hours after the last dose of the previous medicine. ㆍIf a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. Patients with renal impairment No dose adjustment is needed in patients with renal impairment. Patients with hepatic impairment No dose adjustment is needed in patients with mild hepatic impairment. This medicine has not been studied in patients with severe hepatic impairment, and there is limited experience with its use in patients with moderate hepatic impairment.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age (see the Other section).

This medication prevents platelet aggregation in the blood to avoid clot formation. However, it may increase the risk of bleeding, thus it should not be used by patients with bleeding conditions or a prior history of intracranial hemorrhage. If surgery is planned, this medication should be discontinued at least 5 days prior, and any signs of bleeding must be immediately reported to medical personnel. It should not be administered to patients with allergies to any of its components or those with severe liver impairment. Furthermore, concomitant use with certain strong CYP3A4 inhibitors, such as specific antibiotics or antiviral agents, should be avoided as it may excessively elevate the drug's concentration and pose risks. Caution must be exercised in patients at high risk of bleeding or those taking other medications that affect blood coagulation, especially when combined with warfarin, as this may increase bleeding risk. While taking this medication, sudden shortness of breath, dizziness, irregular heartbeat, or severe bleeding symptoms may occur, necessitating immediate consultation with a doctor if any such symptoms arise. Women who are pregnant or breast-feeding must discuss prior to administering this medication, and women of childbearing age planning pregnancy should practice adequate contraception during the treatment period. Safety and effectiveness in children under 18 years have not been established, hence it is not recommended. Overdose may further increase the risk of bleeding, so it is crucial to adhere to prescribed dosages and methods. Caution is also needed while driving or operating machinery due to the potential for dizziness or confusion during this medication's use. Finally, this medication should be stored in its original container and kept out of reach of children.

• Hemorrhage
• intracranial hemorrhage
• ocular hemorrhage
• ear hemorrhage
• hypotension
• dyspnea
• respiratory hemorrhage
• gastrointestinal hemorrhage
• diarrhea
• nausea

This medication must be stored in a tightly sealed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature.

Appearance

Yellow, double convex, round film-coated tablet

Package unit

56 tablets/PTP[(14 tablets/PTP × 4)]